Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029680 | 0.87 | PKM (0.60) | PKMPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL18235383 | 0.85 | PKM (0.49) | PKMPOLBKMT2AALDH1A1LMNA | |
| SCHEMBL31052729 | 0.82 | GAA (0.57) | PKMPOLBKMT2AMEN1LMNA | |
| SCHEMBL18227953 | 0.81 | PKM (0.45) | PKMPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL15412963 | 0.78 | PKM (0.58) | PKMPOLBKMT2AALDH1A1LMNA | |
| SCHEMBL520939 | 0.78 | PKM (0.76) | PKMPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL521032 | 0.75 | LMNA (0.48) | PKMPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL13011203 | 0.74 | POLB (0.49) | PKMPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL2661411 | 0.74 | PKM (0.52) | PKMPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL16943108 | 0.74 | POLB (0.49) | PKMPOLBKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332905-A | (S) -N-phenyl-1- (pyridin-2-yl) pyrrolidine-2-carboxamide derivatives | 上海翊石医药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-3860976-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2021-08-11 | — | — | EP | disclosed |
| CN-113227049-A | Indolinone compounds as MAP4K1 inhibitors | 艾科诺斯科技股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020070331-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2020-04-09 | — | — | WO | disclosed |
| US-10414769-B2 | 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-09-17 | — | — | US | disclosed |
| US-20180141948-A1 | NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2-YL)-(1H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1R/IR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141948-A1 | NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2-YL)-(1H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1R/IR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-05-24 | — | — | US | disclosed |
| WO-2016180843-A1 | NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2- YL)-(1 H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1 R/IR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-17 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414769-B2 | 5,8-dimethyl-9-phenyl-5,8-dihydro-6H-pyrazolo[3,4-h]quinazolin-2-yl)-(1H-pyrazol-3-yl)-amines as IGF-1R/IR inhibitors | IGF1R, IGFBP1, INSR | PKM 862/4885POLB 2901/4885KMT2A 2028/4885 |
| US-20180141948-A1 | NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2-YL)-(1H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1R/IR INHIBITORS | IGF1R, IGFBP1, IRS1 | PKM 1265/4885POLB 3153/4885KMT2A 2179/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | PKM 2336/4885POLB 860/4885KMT2A 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.